Teva, Mylan Compete For Merck KGaA's Generics Arm

The race for the generics business of Germany's Merck KGaA looks to be heading into the final stages with two firms thought to be leading the bidding - Israel's Teva , and US-based Mylan. At the time of press, Teva appears to have the upper hand, due to its larger market cap, although company officials have been silent on the possibility of a deal. However, Mylan could still surprise with an aggressive offer.

To read the full article, please choose one of the following options: